For this reason, the concomitant inhibition of CD39 and CD73 activity could represent an innovative pharmacological strategy in cancer therapy, aimed at counteracting tumor growth by awakening the anti-tumor immunity. The gene discussed is ENTPD1; the disease is neoplasm.